Bacteriophages as anti-infective agents: Recent developments and regulatory challenges

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 5, 2012, Pages 533-535

  Gilmore, Brendan F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

bacteriophage; biofilm; Campylobacter jejuni biofilm; clinical trial; Clostridium difficile; phage delivery

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; POLYMER; REAGENT;

BACTERIAL VIRULENCE; BACTERIOPHAGE; BIOCHEMISTRY; BIOFILM; BIOMEDICINE; BIOTECHNOLOGY; CLOSTRIDIUM DIFFICILE INFECTION; CONFERENCE PAPER; DEVICE INFECTION; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG FORMULATION; DRUG LEGISLATION; ENTEROBACTERIACEAE INFECTION; EUROPEAN UNION; HUMAN; LUNG INFECTION; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; NONHUMAN; PECTOBACTERIUM CAROTOVORUM; PSEUDOMONAS INFECTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOFILMS; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LEGISLATION, DRUG; VIRUS REPLICATION;

EID: 84862533405     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.30     Document Type: Conference Paper

References (12)

1. Nale JY, Shan J, Hickenbotham PT, Fawley WN, Wilcox MH, Clokie MRJ. Diverse temperate bacteriophage carriage in Clostridium difficile 027 strains. PLoS ONE 7(5), e37263 (2012).
2. Connerton PL, Timms AR, Connerton IF. Campylobacter bacteriophages and bacteriophage therapy. J. Appl. Microbiol. 111(2), 255-265 (2011).
3. Siringan P, Connerton PL, Payne RJ, Connerton IF. Bacteriophage-mediated dispersal of Campylobacter jejuni biofilms. Appl. Environ. Microbiol. 77(10), 3320-3326 (2011).
4. Scott AE, Timms AR, Connerton PL, Loc Carrillo C, Adzfa Radzum K, Connerton IF. Genome dynamics of Campylobacter jejuni in response to bacteriophage predation. PLoS Pathog. 3(8), e119 (2007).
5. Debarbieux L, Leduc D, Maura D et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201(7), 1096-1104 (2010).
6. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: First steps towards treatment and prevention. PLoS ONE 6(2), e16963 (2011).
7. Fineran PC, Blower TR, Foulds IJ, Humphreys DP, Lilley KS, Salmond GPC. The phage abortive infection system, ToxIN, functions as a protein-RNA toxin-Antitoxin pair. Proc. Natl Acad. Sci. USA 106(3) 894-899 (2009).
8. Blower TR, Salmond GP, Luisi BF. Balancing at survivals edge: The structure and adaptive benefits of prokaryotic toxin-Antitoxin partners. Curr. Opin. Struct. Biol. 21(1), 109-118 (2011).
9. Carson L, Gorman SP, Gilmore BF. The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol. Med. Microbiol. 59(3), 447-455 (2010).
10. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: How delivery routes, formulation, concentration and timing influence the success of phage therapy. J. Pharm. Pharmacol. 63(10), 1253-1264 (2011).
11. Garland MJ, Migalska K, Mahmood TM, Singh TR, Woolfson AD, Donnelly RF. Microneedle arrays as medical devices for enhanced transdermal drug delivery. Expert Rev. Med. Devices 8(4), 459-482 (2011).
12. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34(4), 349-357 (2009).